ACE and cardiovascular disorder: This was also suggested by secondary analyses of the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and Telmisartan Randomized Assessment Study in Angiotensin-Converting Enzyme–Intolerant Subjects With Cardiovascular Disease studies, where treatment with either angiotensin receptor blocker or an angiotensin-converting enzyme inhibitor among those with severely elevated albuminuria attenuated odds of cognitive decline.39